Literature DB >> 1665491

Combined chemo- and radiosensitivity testing with ifosfamide and ACNU in human lung cancer cell lines.

M Wolf1, M Maasberg, R Pfab, K Havemann.   

Abstract

The combination of radiotherapy and cytostatic drugs is of interest in the treatment of several solid tumors. In these preclinical investigations we tested whether ifosfamide and ACNU are able to enhance radiation effects. The experiments were performed by using the MTT assay. Two small cell and 2 non small cell lung cancer cell lines were involved. Ifosfamide, ACNU or both drugs together were tested in 6 different concentrations adjusted to the peak blood level. During the 1 hour drug incubation time, the cell lines were either irradiated with a single dose of 4 Gy or not. The main results were that ACNU possessed only little cytostatic activity in the cell lines under examination. In contrast, ifosfamide caused a dose related cytostatic activity in all cell lines. Concentrations of 26 micrograms/ml (NCC-SCLC H 82) or 10-12 micrograms/ml (3 other cell lines) were able to reduce the surviving cell fraction to less than 50% (IC50). While ACNU showed no clear outlined radiosensitizing properties, ifosfamide reinforced the radiation effects in 3 out of 4 cell lines indicating radiosensitizing properties of this drug. Synergistic effects of ifosfamide and ACNU have not been noticed. These preclinical investigations may constitute the basis for combined ifosfamide and irradiation therapy in future clinical trials.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1665491     DOI: 10.1007/bf01613225

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  10 in total

1.  Characterization of two cell lines with distinct phenotypes established from a patient with small cell lung cancer.

Authors:  G Bepler; G Jaques; K Havemann; A Koehler; B E Johnson; A F Gazdar
Journal:  Cancer Res       Date:  1987-04-01       Impact factor: 12.701

2.  Radiation-induced DNA damage and lethality in E. coli as modified by the antitumor agent cis-dichlorodiammineplatinum (II).

Authors:  R C Richmond; J D Zimbrick; D L Hykes
Journal:  Radiat Res       Date:  1977-08       Impact factor: 2.841

3.  Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma.

Authors:  M J Lind; J M Margison; T Cerny; N Thatcher; P M Wilkinson
Journal:  Cancer Res       Date:  1989-02-01       Impact factor: 12.701

4.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

5.  Establishment and identification of small cell lung cancer cell lines having classic and variant features.

Authors:  D N Carney; A F Gazdar; G Bepler; J G Guccion; P J Marangos; T W Moody; M H Zweig; J D Minna
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

6.  Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines.

Authors:  G Bepler; A Koehler; P Kiefer; K Havemann; K Beisenherz; G Jaques; C Gropp; M Haeder
Journal:  Differentiation       Date:  1988       Impact factor: 3.880

7.  [Results of 2 multicenter therapy studies in inoperable non-small cell bronchial cancer].

Authors:  M Wolf; K Havemann; D Stalleicken; C Gropp; M Maasberg; K Hans; F von Bültzingslöwen; H Klasen; H Becker; M Schroeder
Journal:  Onkologie       Date:  1988-10

8.  Enhancement of the potentiation of radiotherapy by platinum drugs in a mouse tumor.

Authors:  E B Douple; R C Richmond
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982 Mar-Apr       Impact factor: 7.038

9.  [Cisplatin as a radiosensitizer in the treatment of solid tumours--a clinical pilot study].

Authors:  M Higi; D Schreiber; D Arndt; A Henning; G Schmitt
Journal:  Strahlentherapie       Date:  1982-10

10.  Pharmacokinetics of a new water-soluble nitrosourea derivative (ACNU) in human gliomas.

Authors:  K Harada; K Kiya; T Uosumi
Journal:  Surg Neurol       Date:  1981-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.